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It has long been known that excessivemitotic activity due to H-Ras can block keratinocyte differentiation and
cause skin cancer. It is not clear whether there are any innate surveillants that are able to ensure that kera-
tinocytes undergo terminal differentiation, preventing the disease. IKKa induces keratinocyte terminal differ-
entiation, and its downregulation promotes skin tumor development. However, its intrinsic function in skin
cancer is unknown. Here, we found that mice with IKKa deletion in keratinocytes develop a thickened epider-
mis and spontaneous squamous cell-like carcinomas. Inactivation of epidermal growth factor receptor
(EGFR) or reintroduction of IKKa inhibits excessive mitosis, induces terminal differentiation, and prevents
skin cancer through repressing an EGFR-driven autocrine loop. Thus, IKKa serves as an innate surveillant.INTRODUCTION
Keratinocytes constitute the stratified epidermis, the largest and
most rapidly renewing organ in the body (Blanpain et al., 2007).
Keratinocytes in the basal epidermis are mitotic, providing new
cells to replace those that are shed. After moving to the supra-
basal layers, the cells gradually differentiate and give rise to
the tough, soft cornified layer at the surface of the skin that pro-
tects the internal organs. Each cell renewal cycle takes approx-
imately 4 weeks. Stem cells in the epidermis and hair follicles
also provide cells needed in case of ‘‘emergent cell loss,’’ such
as injury. Therefore, a balance between keratinocyte proliferation
and differentiation is required to maintain epidermal homeosta-
sis. Numerous extrinsic or intrinsic factors can trigger keratino-
cytes to produce a broad spectrum of growth factors and
cytokines, influencing their differentiation and proliferation.
Maintaining proper cellular responses to various stimuli is there-
fore a prerequisite for preventing skin disorders.
The mitogenic signaling cascade from epidermal growth
factor receptor (EGFR), Ras, and extracellular signal-regulated212 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inckinase (ERK) to transcription factors, activating gene expression
of growth factors including EGFR ligands, has been implicated in
the regulation of keratinocyte proliferation and differentiation
(Dlugosz et al., 1997). More than two decades ago, Yuspa and
colleagues (1985) demonstrated that oncogenic v-H-Ras
induces keratinocyte proliferation and transformation but blocks
terminal differentiation. The pathology of Ras-induced keratino-
cyte-derived cancer resembles human squamous cell
carcinomas (SCCs). The chemical carcinogen 7,12-dimethyl-
benz[a]anthracene (DMBA) activates H-Ras to initiate skin tu-
mors (Balmain and Pragnell, 1983). The activating Rasmutations
and elevated Ras-related pathways, as well as elevated activity
of EGFR and its ligands, have also been seen in human SCCs
(Leong et al., 2004; Pierceall et al., 1991). Thus, elevated activity
along this cascade provides the molecular basis for the promo-
tion of keratinocyte proliferation, dedifferentiation, and transfor-
mation. On the other hand, inactivation of EGFR has been found
to inhibit Ras-mediated keratinocyte proliferation and to
promote differentiation in vitro, as well as to prevent skin tumors
induced by overexpression of a dominant form of son ofSIGNIFICANCE
Squamous cell carcinoma (SCC) derived from epithelial cells in many organs is one of the most common malignancies in
humans. Downregulation of IKKa has been reported in SCCs of the skin, esophagus, lungs, and head and neck in humans,
highlighting the importance of IKKa in human cancers. Although a reduction in IKKa expression promotes chemical carcin-
ogen-induced SCCs, it is unknown whether IKKa deletion can cause skin SCCs. Here we show that IKKa deletion in kera-
tinocytes induces skin SCCs in mice through upregulating transcription of EGFR ligands and ligand activators, thus activat-
ing the EGFR-driven pathway. Inactivation of EGFR prevents the development of epidermal hyperplasia and tumors. These
findings shed light on therapeutic targets for preventing IKKa-related SCC development..
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facilitates the GDP-GTP exchange of Ras protein (Sibilia et al.,
2000). Thus, EGFR may serve as a switch point for keratinocyte
proliferation and differentiation. However, it is unknown whether
there are any surveillants that can antagonize the cascade activ-
ity to balance keratinocyte proliferation and differentiation.
Gene disruption studies have demonstrated that the epidermis
of Ikka/ newbornmice lacks a terminally differentiated cornified
layer and exhibits marked thickening; these mice die soon after
birth (Hu et al., 1999; Takeda et al., 1999). Reintroduction of
IKKa or kinase-inactive IKKa induces keratinocyte terminal differ-
entiation and represses hyperproliferation in vitro and in vivo
(Hu et al., 2001; Sil et al., 2004). These findings underscore a piv-
otal role for IKKa in regulating keratinocyte proliferation and differ-
entiation. Furthermore, our recent studies have shown that re-
duced IKKa expression provides a selective growth advantage
that cooperates with Ras activity to promote the formation of
benign and malignant skin tumors induced by DMBA/12-O-tetra-
decanoylphorbol-13-acetate (TPA) (Park et al., 2007). Loss of het-
erozygosity, a classical tumor suppressor feature, is found inmost
carcinomas in Ikka+/ mice, and somatic Ikka mutations are de-
tected in Ikka+/+carcinomas.Also, Ikkagenetic alterationsandepi-
genetically downregulated IKKa expressionhavebeen reported to
be associated with dedifferentiation, invasion, and progression of
human SCCs (Liu et al., 2006;Maeda et al., 2007). Thus, IKKamay
regulatemitogenic activity andRas activity in keratinocyteprolifer-
ation, differentiation, and skin tumor development.
Differentiation is thought to require the withdrawal of keratino-
cytes from the cell cycle (Dlugosz et al., 1997; Gandarillas and
Watt, 1997). Activated Ras has been suggested to increase the
S phase, so that the enhanced cell progression is able to block
the exit of keratinocytes from the cell cycle, thereby preventing
differentiation (Dlugosz et al., 1997). We previously reported that
there aremore bromodeoxyuridine (BrdU)-labeled keratinocytes,
an indicator of S phase, in IKKa null than in wild-type (WT) mouse
epidermis (Hu et al., 1999). An elevated S phase and a reduced
G2/M phase are detected in primary cultured, undifferentiated
Ikka/ keratinocytes (Hu et al., 2001; Zhu et al., 2007). The re-
expression of IKKa rescues these cell-cycle defects. Thus, IKKa-
loss-enhanced cell progressionmayprevent keratinocyte terminal
differentiation by utilizing this cell-cyclemechanism.However, the
pathway that IKKa uses to regulate this switch between keratino-
cyte proliferation and differentiation remains to be defined.
IKKa, IKKb, and IKKg (NEMO) form the IKK complex that acti-
vates NF-kB by phosphorylating IkBs, the inhibitors of NF-kB
(Ghosh and Karin, 2002). Although IKKa and IKKb are highly con-
served protein kinases, IKKb shows a stronger kinase activity for
IkBs than IKKa does. Mice with deletion of IKKb or IkBa in the
basal epidermis develop tumor necrosis factor receptor
(TNFR)-dependent skin inflammation, and mice overexpressing
IkBa in the basal epidermis develop TNFR-dependent skin tu-
mors (Lind et al., 2004; Pasparakis et al., 2002; Rebholz et al.,
2007). However, mice overexpressing IKKa in the basal or supra-
basal epidermis have normal skin and develop fewer SCCs and
metastases induced by DMBA/TPA than WT mice do (Liu et al.,
2006; Sil et al., 2004). Elevated IKKa expression has been found
to enhance terminal differentiation and antagonize chemical
carcinogen-induced mitogenic and angiogenic activities.
Conversely, reduced IKKa expression results in elevated mito-Cagenic and angiogenic activities (Park et al., 2007). Thus, these
physiological functions of IKKa in the skin ofmice extend beyond
NF-kB signaling alone.
However, a study has suggested that IKKa-mediated kerati-
nocyte differentiation is not cell autonomous (Gareus et al.,
2007), which is inconsistent with the phenotypes of IKKa-defi-
cient mice and keratinocytes described above. Also, the function
of IKKa in adult mice has not been revealed. Thus, we generated
mice with IKKa deletion in keratinocytes and investigated the
role of IKKa in skin homeostasis and skin cancer development.
RESULTS
IKKa Deletion in Keratinocytes Causes Thickened
and Wrinkled Skin in Mice
To determine the function of IKKa in the skin of mice, we gener-
ated mice with a floxed Ikka allele (IkkaF/F) (see Figures S1A–
S1D available online). Genotyping confirmed that the number of
IkkaF/F homozygotes matched the expected Mendelian ratio.
To study the role of IKKa in the epidermis, we crossed IkkaF/F
mice with mice expressing Cre under the control of the keratin
5 (K5) promoter, which is expressed in basal epidermal keratino-
cytes, to generate IkkaF/F/K5.Cre mice. It has been documented
that K5.Cre or K14.Cre is expressed in oocytes of female mice,
which leads to germline mutations (Hafner et al., 2004; Ramirez
et al., 2004). The expression of paternally transmitted K5.Cre
was reported in the mouse epidermis at embryonic day 15.5.
As expected, the appearance, skins, and skeletons of IkkaF/F/
K5.Cre mice generated from male IkkaF/F and female IkkaF/+/
K5.Cre mice were identical to those of Ikka/ mice (Figure 1A;
Figures S2 and S3) (Hu et al., 1999; Takeda et al., 1999). Western
blotting showed no IKKa expression in multiple organs obtained
from IkkaF/F/K5.Cre mice (Figure 1B). IkkaF/F/K5.Cre newborns
generated from female IkkaF/F and male IkkaF/+/K5.Cre mice
were indistinguishable from WT (IkkaF/F) mice (P1, Figure 1C).
Byday5, however, the skin of IkkaF/F/K5.Cremicewasnoticeably
more wrinkled and thicker, and mice gradually showed retarded
development (P11, Figure 1C). Most mutant mice died between
12 to 16 days after birth; a few survived longer, but no longer
than 22 days. No food was found in the stomachs of the dead
mice (Figure S4A), and the esophagus was smaller in mutant
mice than in WT mice (Figure S4B). A similar phenotype has
been described in Ikka/ mice, which might be relevant to the
mouse deaths (Hu et al., 1999; Sil et al., 2004). Western blotting
detected a low level of IKKa in the epidermis of mutant mice at
day 1 after birth, and a further reduction of IKKa expression
was observed later (Figure 1D), which was consistent with the
loss of the WT Ikka allele in DNA isolated from the epidermis of
themice (Figure S5). IKKa expressionwas reduced in the tongue,
esophagus, and intestine of IkkaF/F/K5.Cre mice but was normal
in the dermis, liver, lung, spleen (B cells), stomach, thymus
(T cells), bone, brain, heart, kidney, and bone marrow and blood
cells (hematopoietic cells) in IkkaF/F/K5.Cre mice compared with
WT mice (Figure 1E). The level of IKKa expression depended on
whether any Ikka alleles remained (Figure 1E). These results indi-
cate that K5.Cre deletes IKKa specifically in the cells that express
K5 in IkkaF/Fmice. To evaluate the effect of mouse genetic back-
grounds on these phenotypes, we backcrossed IkkaF/F and
K5.Cre mice with C57BL/6 or FVB mice for five generations. Anncer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 213
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IKKa Prevents Skin CancersFigure 1. IKKa Deletion in Keratinocytes Causes Skin Defects in Postnatal Mice
(A) Appearance of IkkaF/F (F/F) and IkkaF/F/K5.Cre (F/F/Cre) mice at birth. The female symbol indicates maternally transmitted K5.Cre.
(B) IKKa levels in different organs of mice in (A), as detected by western blotting. NS, nonspecific band.
(C) Appearance of IkkaF/F (F/F) and IkkaF/F/K5.Cre (F/F/Cre) mice at postnatal days 1 and 11 (P1 and P11). The male symbol indicates paternally transmitted
K5.Cre.
(D and E) IKKa levels in the epidermis of IkkaF/F (W) and IkkaF/F/K5.Cre (M) mice in (C), as detected by western blotting. NS, nonspecific bands; b-Tu, b-tubulin as
loading control; Blood, blood cells; Epide, epidermis; Splee, spleen; Stom, stomach; Thym, thymus; Esop, esophagus; Intest, intestine; WT, wild-type.
(F) Appearance of WT and maternally transmitted IkkaF/F/K5.Cre/K5 (Res-Mut) newborns.
(G) IKKa levels in the skins of mice in (F), as detected by western blotting. K5, K5.IKKa transgene; HA-IKKa, HA-tagged IKKa transgene expression.
(H) Appearance of WT and paternally transmitted IkkaF/F/K5.Cre/K5 (Res-Mut) mice at 4 weeks of age.
(I) IKKa levels in the epidermis of mice in (H), as detected by western blotting. b-actin was used as a loading control.FVB background was found to confer a slight increase in skin
thickness and slightly earlier death compared to aC57BL/6back-
ground (data not shown). Collectively, these results suggest that
a low level of IKKa in the epidermis is sufficient for normal embry-
onic skin development but that a further reduction causes skin
lesions.
To verify that these phenotypes in IkkaF/F/K5.Cre mice were
due to an IKKa-specific deletion in keratinocytes, we re-ex-
pressed a keratinocyte-specific K5.IKKa transgene in IkkaF/F/
K5.Cre mice (Lomada et al., 2007). K5.IKKa expression rescued
the skin phenotype ofmaternally transmitted IkkaF/F/K5.Cremice
(Figures 1F and 1G; Figure S6A), but the rescued mice died soon
after birth, which was consistent with observations in previous214 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Increports (Lomada et al., 2007; Sil et al., 2004). K5.IKKa expression
completely rescued paternally transmitted IkkaF/F/K5.Cre mice
(Figures 1H and 1I; Figure S6B). No skin disorders were found
in adult IkkaF/F/K5.Cre/K5.IKKa mice. Thus, IKKa deletion
causes the skin phenotypes in IkkaF/F/K5.Cre mice.
IKKa Deletion Causes Epidermal Keratinocyte
Hyperproliferation and Deregulates Expression
of Many Genes
Histologies of the skins from WT and IkkaF/F/K5.Cre mice were
almost identical on days 1 and 3 (Figure 2A), which reflected
their normal appearances. From days 6 to 22, the epidermal
thickness in mutants gradually increased (Figure 2A). The total.
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IKKa Prevents Skin Cancersnumber of keratinocytes in the epidermis was significantly
higher in mutants than in WT mice. Immunohistochemical stain-
ing showed that the entire mutant epidermis expressed K5 and
gradually reduced K10 with increased epidermal thickness
(Figure S7). The thickened mutant epidermis did not express
the terminal differentiation markers loricin and filaggrin, although
the markers were weakly detected on the surface of the skin
(Figure S7). These results suggest that hyperproliferation may
prevent terminal differentiation in keratinocytes. We also exam-
ined CD34-positive keratinocytes, which have been identified as
follicular stem cells (Blanpain et al., 2004; Morris et al., 2004).
Hair follicles are still developing in mice at age 1 to 16 days;
thus, the hair follicle of an adult mouse was used as a control
for CD34-positive cells in the hair follicle (Figure 2B). Immunohis-
tochemical staining showed that the number of CD34-positive
keratinocytes was similar in hair follicles of WT and mutant
mice, although the total number of keratinocytes was greater
in mutant hair follicles than in WT hair follicles (Figure 2B;
Figure S7), suggesting that IKKa deletion may have a stronger
impact on proliferation of CD34-negative keratinocytes than on
CD34-positive keratinocytes.
Micewithkeratinocyte-specific IKKadeletionbyK14.Cregener-
ated in a previous study diedat birth (Gareus et al., 2007). Although
Figure 2. IKKa Deletion Causes Epidermal
Hyperplasia
(A) Histology of mouse skins stained with hema-
toxylin and eosin (H&E). Day, postnatal day; WT,
wild-type mice; Mut, IkkaF/F/K5.Cre mice. Arrows
indicate epidermis. Scale bars = 30 mm.
(B) Brown indicates CD34-positive cells (cells indi-
cated by arrows are shown enlarged in boxes at
right); blue indicates nuclear counterstaining.
Adult sample is shown as a control for CD34-pos-
itive cells in the bulge (B). SG, sebaceous gland.
Scale bars = 30 mm.
it is difficult to speculate on the observa-
tions of Gareus et al. (2007) because the
authors did not describe in detail how
they generated their mice, we attempted
to clarify the differences by generating
IkkaF/F/K14.Cre mice. Paternally transmit-
ted IkkaF/F/K14.Cre and IkkaF/F/K5.Cre
mice showed similar skin phenotypes
(Figure S8A). Someof thematernally trans-
mitted IkkaF/F/K14.Cre mice recapitulated
the phenotype of Ikka/ mice
(FigureS8B), andothersdevelopedepider-
mal hyperplasia after birth (data not
shown). Ramirez et al. (2004) observed
a partial gene deletion pattern in oocytes
in some cases by Cre, whichmight explain
these different phenotypes.
Next, we determined mitotic activity in
the epidermis using immunohistochemi-
cal staining. We found that the prolifera-
tion marker Ki67 was significantly more
abundant in IkkaF/F/K5.Cre epidermis
than in WT epidermis (Figure 3A). BrdU-positive cells were con-
sistently more numerous in mutant epidermis than in WT epider-
mis (Figures S9A and S9B), and expression of K6, which is highly
elevated in abnormally proliferating epidermis, was elevated in
mutant epidermis (Figure 3A). The abnormally proliferating epi-
dermis may promote dermal cell proliferation or attract macro-
phages or lymphocytes. Thus, we found a slightly increase in
macrophages (F4/80) but no increase in T (CD3) or B (CD45R)
cells (Pasparakis et al., 2002) in the stroma of 6-day-old mutants
(Figure S10A). Also, TNFa expression was higher in IKKa null
than in WT keratinocytes (Figure S10B).
To determine whether the epidermal hyperplasia is intrinsic to
IKKa-deficient keratinocytes, we cultured keratinocytes isolated
from IkkaF/F/K5.Cre and WT newborns. Cell growth curves
showed that mutant cells grew more rapidly than WT cells
(Figure 3B). WT keratinocytes had terminally differentiated mor-
phologies (Hu et al., 2001), whereas mutant cells did not
(Figure 3C). Also, mutant cells formed many more and larger col-
onies than WT cells did (Figure 3D). Thus, IKKa deletion induces
keratinocyte-autonomous hyperproliferation.
To determine which signaling pathways may promote cell pro-
liferation, we compared the transcriptional profiles of genes
in WT and mutant keratinocytes using microarray analysesCancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 215
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IKKa Prevents Skin Cancers(Table S1). As shown in Figure 3E, upregulated genes in mutants
included those encoding EGFR, EGFR ligands, Braf, FGF13,
IGF2, and PDGFa; a group of integrin genes; ADAM19,
MMP10, and MMP9; Notch ligands; the Wnt inhibitors Dkk3
and Dkk2; and various Wnts. Downregulated genes included
those encoding Wnt7a, Notch3, and a group of claudins (Fig-
ure 3E; Table S1). Such a broad collection of deregulated genes
indicates that IKKa may have a broad impact on skin biology.
IKKa Downregulates an Autocrine Loop of EGFR, ERK,
EGFR Ligands, and a Group of ADAMs in the Epidermis
and in Keratinocytes
To determine the signaling pathways responsible for hyperprolif-
eration and dedifferentiation in IKKa-deficient cells (Figure 3E),
we examined the EGFR-driven pathway because it has been
Figure 3. IKKa Deletion Causes Keratino-
cyte Hyperproliferation and Deregulates
Expression of Many Genes
(A) Immunohistochemistry of skin sections stained
for Ki67 and K6. P, postnatal day; WT, wild-type;
Mut, IkkaF/F/K5.Cre. Dark brown color indicates
positive cells; blue color indicates nuclear coun-
terstaining. Scale bars = 50 mm.
(B) Keratinocyte growth curve. Equal numbers of
cells from newborns were plated in cultures, and
cell growth was statistically analyzed at the indi-
cated days (n = 8). Error bars indicate ±SD.
(C) Keratinocyte morphologies in culture at day 4.
Scale bars = 50 mm.
(D) Keratinocytes colony formation at day 10. Cell
colonies were stained with 0.5% crystal violet
solution.
(E) Summary of microarray analysis results for cul-
tured keratinocytes. Gene upregulation and down-
regulation are in IkkaF/F/K5.Cre cells compared to
WT cells. References for each gene’s functions
can be found by searching the NCBI Entrez Nucle-
otide database (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=nuccore&itool=toolbar) using the
‘‘Systematic Name’’ entry in Table S1.
reported to regulate keratinocyte prolifer-
ation and differentiation (Dlugosz et al.,
1997). Also, the activity of ERK, a down-
stream target of EGFR, was previously
found to be elevated in IKKa-deficient
keratinocytes (Park et al., 2007; Sil et al.,
2004). Western blotting showed more
EGFR and ERK activity in mutant than in
WT epidermis (Figures 4A and 4B). Be-
cause EGFR ligands activate EGFR and
the appearance of IkkaF/F/K5.Cre mice
resembles that of mice expressing in-
creased soluble forms of heparin-binding
EGF (HB-EGF) (Yamazaki et al., 2003), we
examined levels of EGF and HB-EGF.
Using western blotting, we found higher
levels of mature EGF and HB-EGF and
lower levels of EGF and HB-EGF precur-
sors in mutant than in WT epidermis
(Figure 4C). It is known that A disintegrin and metalloprotease
(ADAM) sheddases cleave EGF and HB-EGF precursors to gen-
erate their active soluble forms (Huovila et al., 2005). Figure 3E
shows that ADAM19was upregulated in IKKa-deficient keratino-
cytes. We thus examined the mRNA levels of ADAM12, 10, 17,
19, and 9 in primary cultured keratinocytes by RT-PCR and
found that their expression levels were higher in Ikka/ than in
WT cells and that stimulation of cell growth elevated these levels
(Figure 4D). Western blotting confirmed elevated levels of
ADAM12, 10, and 17 in mutant epidermis (Figure 4E). The pres-
ence of elevated ADAM10 expression in mutant epidermis was
confirmed by immunofluorescence staining (Figure S11A). Fur-
thermore, zymography (Hall and Erickson, 2003) verified that
ADAMs were more active in mutant than in WT epidermis, and
reintroduction of IKKa repressed this activity (Figure 4F).216 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc.
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IKKa Prevents Skin CancersFigure 4. Elevated Autocrine Loop in IKKa-Deficient Keratinocytes
(A–C) Levels of phosphorylated EGFR (p-EGFR), p-ERK, EGF, precursor EGF (pre-EGF), HB-EGF, and pre-HB-EGF in epidermis ofWT (W) and IkkaF/F/K5.Cre (M)
mice, as detected by western blotting. P, postnatal day. b-tubulin was used as a loading control.
(D) mRNA levels of A disintegrin and metalloproteases (ADAMs) in WT and Ikka/ (/) primary keratinocytes cultured for 1 day with no growth supplement
(Starv) or with growth supplement (Supplem), as detected by RT-PCR. GAPDH was used as a PCR control.
(E) Levels of ADAM12, 10, and 17 in epidermis of WT and IkkaF/F/K5.Cre (M) mice, as detected by western blotting.
(F) Activities of sheddases in epidermis of WT, IkkaF/F/K5.Cre (M), and IkkaF/F/K5.Cre/K5.IKKamice (IKKa+M), as detected by gelatin zymography. WB, western
blotting; * indicates proteins.
(G) Levels of p-EGFR, p-ERK, EGF, HB-EGF, and/or ADAMs in WT keratinocytes, Ikka/ keratinocytes (/), and Ikka/ keratinocytes treated with GM6001
(GM), GW2974 (GW), and/or PD98059 (PD) for 24 hr or with reintroduced IKKa or IKKa-KA after 48 hr, as detected bywestern blotting. b-actin was used as a load-
ing control.
(H) Levels of the indicated proteins in skin of WT, Ikka/ (/), and Ikka//K5.IKKa newborns, as detected by western blotting. NS, nonspecific band. b-tubulin
was used as a loading control.ERK and EGFR are believed to upregulate ADAMs (Huovila
et al., 2005). We therefore hypothesized that IKKa regulates
EGFR-driven mitogenic signaling and ADAM expression through
the same signaling loop. To prove this hypothesis, we treated
IKKa-deficient keratinocytes with inhibitors for a broad spectrum
of ADAMs (GM6001), EGFR (GW2974), and/or ERK (PD98059)
and re-expressed IKKa or a kinase-dead full-length IKKa (withCaa mutation at the ATP-binding site within the kinase domain;
IKKa-KA) in the cells. Western blotting showed reduced EGFR
and ERK activities and EGF, HB-EGF, and ADAM levels but ele-
vated EGF and HB-EGF precursors in mutant keratinocytes after
these treatments (Figure 4G). Similar results were obtained for
transgenic IKKa in the epidermis (Figure 4H). Taken together,
these results suggest that IKKa downregulates the activity ofncer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 217
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keratinocytes.
IKKa Suppresses Promoter Activation of EGF, HB-EGF,
Amphiregulin, and ADAMs
To determine the mechanism of how IKKa prevents EGFR auto-
crine loop activity in keratinocytes, we examined whether IKKa
regulates the transcription of EGFR ligand genes and ADAMs,
because IKKa has been shown to have transcriptional activity
in the keratinocyte nucleus (Liu et al., 2006). Using a chromatin
immunoprecipitation (ChIP) assay, we found that IKKa bound
to the promoters of the EGF (1511 to 1133 bp), HB-EGF
(1911 to 1534 bp), and amphiregulin (AR) (3129 to 2785
bp) genes in Ikka+/+ and Ikka+/ primary cultured keratinocytes,
but not in Ikka/ keratinocytes (Figure 5A). The bonds were
stronger in Ikka+/+ than in Ikka+/ cells. Treatment with TPA (30
ng/ml) attenuated binding of IKKa to these promoters, which
Figure 5. IKKa Regulates Promoter Activi-
ties of EGF, HB-EGF, Amphiregulin, and
ADAMs
(A) Binding of IKKa to promoters of EGF, amphire-
gulin (AR), and HB-EGF, as detected by chromatin
immunoprecipitation (ChIP) assay with an anti-
IKKa antibody for immunoprecipitation. +/+,
Ikka+/+ keratinocytes; +/, Ikka+/ keratinocytes;
/, Ikka/ keratinocytes. TPA was used at 30
ng/ml. No antibody, negative control; Input, PCR
control.
(B) RT-PCR for expression of the indicated genes.
GAPDH was used as an mRNA loading control.
(C) Binding of IKKa to the promoters of the indi-
cated genes. Sta, cells cultured in basic keratino-
cyte culture medium; Con, control. EGF was used
at 10 ng/ml.
(D) Protein structures of IKKa. KD, kinase domain;
LZ, leucine zipper; HLH, helix-loop-helix domain;
stop, stop codon. R/S, T/A, M/V, K/E, S/P, R/K,
N/S, Q/K, Y/C, and E/K indicate amino acid substi-
tutions.
(E) Indicated IKKa protein levels in IKKa-deficient
keratinocytes as detected by western blotting.
Cont, no IKKa. b-actin was used as a loading
control.
(F) Binding of different forms of IKKa to the EGF
promoter, as detected by ChIP assay with an
anti-IKKa antibody for immunoprecipitation. All
samples were compared with IKKa-deficient cells
(Mut). Error bars in (F)–(I) indicate ±SD.
(G) RT-PCR for expression of EGF affected by dif-
ferent forms of IKKa.
(H) Binding of different forms of IKKa (see
Figure S11B) to the EGF promoter, as detected
by ChIP assay. ‘‘300 aa’’ represents a 300 aa
deletion.
(I) RT-PCR for expression of EGF affected by dif-
ferent forms of IKKa.
correlated profoundly with increased ex-
pression of the corresponding genes
(Figure 5B). Treatment with EGF (10 ng/
ml) also reduced binding of IKKa to the
promoters of the EGF, HB-EGF, AR,
ADAM12 (2733 to 2516 bp), ADAM19 (3402 to 3182 bp),
and ADAM17 (2389 to 2073 bp) genes in WT keratinocytes
(Figure 5C), and the addition of growth factors elevated the ex-
pression of these ADAMs (Figure 4D). We found that IKKa failed
to bind to the proximal promoter regions of the genes described
above (data not shown). These results suggest that IKKa sup-
presses the induced expression of EGF, HB-EGF, AR, and
ADAMs by downregulating their promoter activities.
To further elucidate how IKKa regulates gene expression, we
introduced WT IKKa, an 80 aa deletion IKKa (IKKa-C80), and
three IKKamutants (Mut1, Mut2, and Mut3) isolated from poorly
differentiated SCCs into IKKa-deficient keratinocytes (Figures
5D and 5E) (Hu et al., 2001; Liu et al., 2006; Zhu et al., 2007).
ChIP assay and RT-PCR showed that WT IKKa and IKKa-C80
bound to the EGF promoter and suppressed EGF expression;
Mut1 showed incomplete binding activity to the EGF promoter
and a reduced inhibitory effect on EGF expression compared218 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc.
Cancer Cell
IKKa Prevents Skin Cancersto IKKa, andMut2 andMut3 failed to bind to the EGF promoter or
suppress EGF expression (Figures 5F and 5G). WT keratinocytes
were used as controls. Because IKKa-C80 had activity compara-
ble to that of IKKa, the C-terminal deletion in Mut1 andMut2may
not be a major cause of loss of IKKa function. In addition to the
C-terminal deletion, a mutation occurred at the leucine zipper
(LZ) motif in Mut1; Mut2 and Mut3 had multiple mutations in
the helix-loop-helix (HLH) or LZ motif and in the region between
the kinase and LZ domain. To further confirm whether these
motifs of the IKKa protein are required to suppress the activities
of the above promoters, we introduced IKKamutants with muta-
tions in the LZ or HLHdomains (LZ- or HLH-), IKKa-KA, and/or an
N-terminal 300 aa deletion (KD-) (Zhu et al., 2007) into IKKa-de-
ficient keratinocytes (Figure S11B). ChIP assay showed that the
activities of IKKa-KA in binding to the EGF promoter and repres-
sing EGF expression were similar to those of WT IKKa; however,
LZ-, HLH-, and KD- IKKa mutants were not able to bind to the
EGF promoter and failed to suppress EGF expression (Figures
5H and 5I). These results indicate that the LZ and HLH motifs
and protein conformation of IKKa are important for regulation
of gene expression.
IKKa Regulates Keratinocyte Proliferation and
Differentiation through the EGFR-Driven Pathway
To understand whether IKKa regulates keratinocyte proliferation
and differentiation via the EGFR-driven loop, we treated IKKa-
deficient keratinocytes with inhibitors of EGFR (AG1478 and
GW2974), ADAMs (GM6001), and ERK (PD98059) and also rein-
troduced WT, C80, Mut1, Mut2, Mut3, LZ-, HLH-, KD-, and KA
IKKa into these cells. We reported previously that reintroduced
IKKa specifically induces larger terminally differentiated kerati-
nocytes and results in the expression of the terminal differentia-
tion markers loricrin and filaggrin in Ikka/ cells (Hu et al., 2001).
Thus, we used cell morphologies and filaggrin induction to iden-
tify terminally differentiated keratinocytes. The results indicated
that the tested inhibitors, IKKa, IKKa-KA, and IKKa-C80 inhibited
proliferation and induced terminal differentiation in mutant kera-
tinocytes; Mut1 slightly inhibited hyperproliferation and induced
filaggrin to a lesser degree, and Mut2, Mut3, LZ-, HLH-, and KD-
failed to inhibit cell proliferation or induce keratinocyte terminal
differentiation (Figures 6A and 6B). We further compared levels
of filaggrin induced by IKKa, IKKa-C80, and Mut1 in IKKa-defi-
cient cells by diluting these cell lysates to 1/2 and 1/4 and found
that, compared to IKKa and IKKa-C80, Mut1 induced lower
levels of filaggrin (Figure 6C). To test whether the effect of
the EGFR-driven pathway on cell proliferation is related to diffe-
rentiation or apoptosis in IKKa-deficient cells, we further ex-
amined markers of apoptosis in mutant keratinocytes. Using
western blotting, we found that inhibitors of EGFR, ERK, and
ADAMs did not increase apoptosis in mutant keratinocytes
(Figure S11C). Collectively, these results suggest that IKKa and
the EGFR-driven pathway coordinately regulate keratinocyte
proliferation and differentiation and that IKKa activity requires
its functional domains, but not its kinase activity.
Inactivation of EGFR Reverses the Epidermal
Hyperplasia in IkkaF/F/K5.Cre Mice
To further determine the physiological function of the EGFR-
driven loop in IkkaF/F/K5.Cre mice, we inactivated EGFR activityCain IkkaF/F/K5.Cre mice by backcrossing Egfrwa2/wa2 (a kinase-
inactive mutation in EGFR) (Luetteke et al., 1994) with IkkaF/F
and K5.Cre mice to generate IkkaF/F/K5.Cre/Egfrwa2/wa2 mice.
The epidermis of IkkaF/F/K5.Cre/Egfrwa2/wa2 mice was as thin
as that of WT controls, and Ki67-positive cells and EGFR and
ERK activities were decreased in the epidermis (Figure 6D).
Like IkkaF/F/K5.Cre mice, these mice died early. GW2974, ad-
ministered orally, also inhibited epidermal thickening in IkkaF/F/
K5.Cre mice (Figure S12) (Kiguchi et al., 2005). Furthermore,
we generated IkkaF/F/K5.Cre/Egfr/ mice, but these mice died
within 3 days after birth (Sibilia and Wagner, 1995; Threadgill
et al., 1995). Reducing the Egfr gene dosage by half was found
to dramatically decrease epidermal thickness in IkkaF/F/K5.Cre/
Egfr+/ mice, although their epidermis was still slightly thicker
than that of WT mice (Figure 6E). Most of the IkkaF/F/K5.Cre/
Egfr+/ mice died, but a small fraction survived. The surviving
mice developed obvious defects in hair and eyes (Figure 6F). It
is known that Egfr/ mice on the same genetic background
are prone to death during a wide range of ages, which under-
scores the importance of EGFR for individual mouse develop-
ment (Sibilia and Wagner, 1995; Threadgill et al., 1995). Taken
together, these results suggest that a reduction of EGFR activity
can mitigate IKKa-deletion-induced excessive proliferative sig-
nals in the epidermis, thereby reversing epidermal hyperplasia.
Inactivation of IKKa kinase in IkkaK44A/K44Amice was found not
to cause hyperproliferation in the epidermis (Figure S13) (Zhu
et al., 2007). Thus, the increased epidermal thickness in
IkkaF/F/K5.Cre mice is IKKa kinase independent. IKKa loss also
elevated TNFa expression (Figure S10B). Overexpression of
TNFa can cause severe inflammation-dependent skin lesions
in mice (Lind et al., 2004). To determine whether the epidermal
phenotype was TNFa dependent, we generated IkkaF/F/
K5.Cre/Tnfr1/ mice and found that depleting TNFR1 did not
attenuate the epidermal phenotype but did lead to the slightly
earlier death of the mice (Figures S14A and S14B). No significant
alterations in the levels of IKKb, IKKg, p65, p100, p52, and IkBa
or in IKK kinase activity were found in the epidermis of WT or
mutant mice (Figures S15A and S15B). Collectively, these results
show that excessive EGFR-driven loop activity, but not TNFR,
is a primary trigger responsible for inducing the epidermal
hyperplasia in IkkaF/F/K5.Cre mice.
Mice with IKKa Deletion in Keratinocytes Develop
Spontaneous Skin Cancer
To determine whether IKKa deletion in keratinocytes induces
skin tumors, we used mouse mammary tumor virus (MMTV).Cre
mice to delete IKKa. IkkaF/F/MMTV.Cre mice were distinguish-
able from WT mice by their sparse body hair 3 weeks after birth.
We found that 8 of 9 IkkaF/F/MMTV.Cre mice began to develop
spontaneous tumors on their face at 1 to 5 months of age (Fig-
ures 7A and 7B). Because the oldest mice that we observed
were 8 months old, it is possible that the tumor incidence may
reach 100% as the mice get older. These tumors expressed
pan-keratin and resembled SCCs pathologically (Figures 7C).
None of the IkkaF/F or MMTV.Cre mice developed spontaneous
tumors. The dorsal epidermis of IkkaF/F/MMTV.Cre mice was
hyperplastic, with elevated EGFR and ERK activities compared
to WT epidermis (Figure S16).ncer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 219
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IKKa Prevents Skin CancersFigure 6. IKKa Switches Keratinocyte Proliferation and Differentiation via the EGFR Pathway
(A) Effects of different forms of IKKa and the indicated inhibitors on keratinocyte colony formation. WT, IkkaF/F keratinocytes; F/F/K5.Cre, IkkaF/F/K5.Cre kera-
tinocytes. GM, GM6001; AG, AG1478; PD, PD98059; GW, GW2974. Keratinocyte colonies were stained with 0.5% crystal violet.
(B) Keratinocytemorphologies in culture.Cells in small boxes represent terminally differentiatedkeratinocytes.M, IkkaF/F/K5.Crekeratinocytes.Scalebars=40mm.
(C) Filaggrin levels in the indicated keratinocytes, as detected by western blotting. 1, 1/2, and 1/4 represent protein dilutions. b-actin was used as a loading
control.
(D) Effect of inactivation of EGFR on the epidermis in mice at P8.5. Ki67 is shown by dark brown staining with immunohistochemistry, p-ERK by red staining with
immunofluorescence, and p-EGFR by green staining with immunofluorescence. Lines in p-ERK and p-EGFR indicate the limits of the epidermis. Cre, K5.Cre;
W/W, Egfrwa2/wa2. Scale bars = 50 mm.
(E) Skin histology of the indicated mouse genotypes, stained with H&E. Scale bars = 60 mm.
(F) Appearance of the indicated mouse genotypes at 4 months of age.220 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc.
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(Wagner et al., 1997), we investigated whether inducible IKKa
deletion specifically in keratinocytes causes spontaneous skin
tumors. We used inducible K15.Cre, which is specifically ex-
pressed in keratinocytes of hair follicles (Morris et al., 2004), to
delete IKKa in mice using RU846. We treated seven IkkaF/F/
K15.Cre mice with RU846. Four months after treatment, all of
the mice began to develop skin tumors (Figures 7D and 7E).
The appearance of these tumors was similar to that of DMBA/
TPA-induced skin papillomas and malignant carcinomas (Fig-
ures 7D and 7F). The mouse in Figure 7D developed more than
ten tumors. The tumors resembled SCCs pathologically and
expressed pan-keratin (Figure 7F).
We further examined the status of keratinocyte differentiation
and proliferation in WT and IkkaF/F/K15.Cre skin. Western blotting
showed that filaggrin expression was lower in IkkaF/F/K15.Cre
than inWT skin and that treatment with GW2974 elevated filaggrin
expression (Figure7G). In IkkaF/F/K15.Creskin, increasedkeratino-
cyte numbers in hair follicles and epidermis surrounding the hair
follicles and elevated EGFR and ERK activities were detected,
butCD34-positivecellswere restricted in thehair follicle (Figure7H;
Figure S17). GW2974 inhibited hyperproliferation and EGFR
and ERK activities in mutant epidermis (Figure 7H; Figure S17).
Also, seven GW2974-treated IkkaF/F/K15.Cre mice had not de-
veloped any tumors at 6months after treatmentwithRU846, sug-
gesting that inactivation of EGFR induces terminal differentiation,
inhibits proliferation, and prevents tumor development.
Figure 7. IKKa Deletion in Keratinocytes Causes
Spontaneous Skin Cancer
(A) Tumors in an 8-month-old IkkaF/F/MMTV.Cre mouse.
(B) Tumor incidence in IkkaF/F/MMTV.Cre (F/F/MMTV.Cre) and
WT (F/F) mice.
(C) Pathologies of H&E-stained tumor sections from IkkaF/F/
MMTV.Cre mice. Panels at right show a magnification of the
boxed area at left and pan-keratin staining (brown). Black
scale bar = 25 mm; green scale bar = 10 mm.
(D) Tumors in an IkkaF/F/K15.Cre mouse 6 months after
RU486 treatment to induce IKKa deletion. P, papillomas;
C, carcinomas.
(E) Tumor incidence in IkkaF/F/K15.Cre (F/F/K15.Cre) and WT
(F/F) mice.
(F) Pathologies of H&E-stained tumor sections from IkkaF/F/
K15.Cre mice. Panels at right show a magnification of the
boxed area at left and pan-keratin staining (brown). Black
scale bar =25 mm; green scale bar = 10 mm.
(G) Filaggrin levels in skin, as detected by western blotting.
b-actin was used as a loading control.
(H) Skin sections stainedwithH&Eandantibodies againstK5or
CD34. Brown color indicates K5 or CD34 staining. The two ar-
rows in the leftmost H&E panel indicate hair follicles seen in the
K5 and CD34 panels to the right. The arrow in the CD34 panel
indicates CD34 staining. GW, GW2974. Scale bar = 40 mm.
(I) Genotyping. Cont, WT skin; H, heart; L, liver; T, tumor. 1.3
kb, allele containing loxP sites; 1.2 kb, WT allele; 460 bp, Ikka
gene deletion.
The Ikka gene was deleted in all of the tumors
found in IkkaF/F/MMTV.Cre and IkkaF/F/K15.Cre
mice (Figure 7I). Because MMTV.Cre is expressed
in various types of cells, weak deletion bands
were detected in the heart and liver of IkkaF/F/
MMTV.Cre mice (Figure 7I). Taken together, these results indi-
cate that IKKa deletion in keratinocytes can cause skin carcino-
mas, which are accompanied by elevated EGFR and ERK activ-
ities (Figures S16A and S17).
In addition, we generated tamoxifen-inducible IkkaF/F/K5.Cre
mice. The dorsal epidermis of these mice exhibited hyperplasia
(Figure S18A). Four of the eight inducible IkkaF/F/K5.Cre mice
developed skin tumors 10 to 12 months after tamoxifen treat-
ment (Figure S18B). Only one to three tumors per mouse were
observed, and IKKawas deleted in these tumors. Thus, the num-
ber and incidence of skin tumors were lower in inducible IkkaF/F/
K5.Cre mice than in inducible IkkaF/F/K15.Cre mice. The K5 and
K15 promoters are expressed in different subtypes of keratino-
cytes. Keratinocytes expressing K5 are physically closer to
suprabasal differentiating cells than hair follicle keratinocytes
expressing K15. The difference may have an impact on the
susceptibility to tumorigenesis in mice.
ActivatedRas, adownstream targetof EGFRandupstream tar-
get of ERK, is involved in keratinocyte transformation (Yuspa
et al., 1985). We further found that Ras activity was significantly
higher in IKKa null than in WT keratinocytes (Figure 8A). Reintro-
duced IKKa, EGFR inhibitor, or dominant-negative RasN17 sup-
pressed Ras and ERK activities and cell proliferation but induced
terminal differentiation in IKKanull keratinocytes (Figures 8A–8C).
Increased Ras activity was found to suppress terminal differenti-
ation inWTkeratinocytes (Figure8D). Thus, IKKadeletionmayac-
tivate Ras via the EGFR-driven loop in keratinocytes (Figure 8E).Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 221
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IKKa Functions as a Switch for Keratinocyte
Differentiation and Proliferation via the EGFR-Driven
Pathway and Is Required for Skin Homeostasis
Our results here have demonstrated that a low level of IKKa in
keratinocytes is sufficient to maintain embryonic skin develop-
ment in mice. However, further IKKa deletion induced epidermal
hyperplasia in postnatal and adult mice. Epidermal thickness in
mutant mice was found to gradually increase after birth, which
was accompanied by gradually elevated EGFR and ERK activi-
ties and levels of EGFR ligands and ADAMs; this also occurred
in cultured mutant keratinocytes. The hyperproliferative kerati-
nocytes in the epidermis or in cultures lacked terminal differenti-
ation (Figures 6A and 6C; Figure S7). Inactivation of EGFR by
genetic and pharmacological inhibitor approaches as well as
transgenic IKKa was able to suppress keratinocyte hyperprolif-
eration and direct the cells to terminal differentiation, reversing
the epidermal phenotype in mice with IKKa deletion in keratino-
cytes. Furthermore, IKKa and IKKa functional domains were re-
quired to suppress the transcription of EGFR ligands and these
ligands’ activators and to suppress EGFR and ERK activities in
mutant keratinocytes. Taken together, these results provide ev-
idence that IKKa regulates keratinocyte proliferation and differ-
entiation through the EGFR-driven loop, which is required for
maintaining skin homeostasis in mice.
Quantitation assays showed that mutations in Ikka (Mut1) im-
paired the capacity of IKKa to induce terminal differentiation and
suppress hyperproliferation at the same time in IKKa-deficient
keratinocytes (Figures 6A and 6C), providing further, direct evi-
dence that IKKa is a switch for keratinocyte proliferation and dif-
ferentiation; the integrity of Ikka, but not its kinase activity, is
required for this switch. Previously, we showed that culture
medium obtained fromWT keratinocytes was able to temporarily
induce terminal differentiation in Ikka/ keratinocytes (Hu et al.,
2001), which was inactivated by treatment with trypsin or heat
(90C). The proteinaceous factor was named keratinocyte differ-
entiation-inducing factor (kDIF). We also suggested that the
grafted Ikka/ skin was induced to undergo terminal differenti-
ation by kDIF from surrounding WT keratinocytes in mice (Hu
et al., 2001). Our findings here further explain this transplant re-
sult. We had previously placed Ikka/ skin in basic keratinocyte
culture medium at 4C for longer than overnight before grafting
(Hu et al., 2001). Such conditions might affect the ability of the
Ikka/ keratinocytes to proliferate, causing them to instead un-
dergo terminal differentiation. Thus, in addition to secreted kDIF,
which may include inhibitors of components of the EGFR-driven
loop, intrinsic conditions also regulate the status of IKKa-defi-
cient keratinocytes.
Although here we found that depleting TNFR was not able to
prevent the development of epidermal hyperplasia in IkkaF/F/
K5.Cremice (Figure S14), the elevated TNFamay affect late phe-
notypes in these mice. Also, inflammatory cells in the dermis
(Figure S10A) may contribute to epidermal cell proliferation in
mutant mice. IKKa loss was previously found to upregulate vas-
cular endothelial growth factor expression (Liu et al., 2006). In-
deed, an increase in blood microvessels was observed in the
skin of IkkaF/F/K5.Cre mice (data not shown). In addition, we
observed very short hair in surviving IkkaF/F/K5.Cre/Egfr+/ mice
and sparse hair in IkkaF/F/MMTV.Cre mice, suggesting that
IKKa plays a role in hair development, although the mechanism
remains to be elucidated. Moreover, our microarray analyses
revealed the elevated expression of multiple integrins, various
growth factors, matrixmetalloproteases (MMPs), Notch receptor
ligands, Wnts, andWnt inhibitors in IKKa-deficient keratinocytes
(Figure 3E). A group of tight-junction proteins, claudins, which
affect barrier formation and hair development, were dramatically
downregulated in mutant keratinocytes (Figure 3E). Taken
together, these molecular alterations may contribute to the
skin phenotypes in mice with IKKa deletion in keratinocytes.
Thus, IKKa plays a broad role in maintaining normal skin.
IKKa Is an Innate Surveillant to Prevent Skin Cancer
In mouse models of skin carcinogenesis, DMBA-activated Ras
or overexpressed Ras in basal or suprabasal keratinocytes can
induce squamous cell-like skin tumors (Brown et al., 1998;
Figure 8. Elevated Ras Activity Incorporates with the
EGFR Pathway in IKKa Null Keratinocytes
(A) Ras activity in keratinocytes as detected by GST pull-down
and western blotting. Elevated Ras and ERK activities were
downregulated by IKKa, inactivation of Ras, and an EGFR
inhibitor. +/+, Ikka+/+ keratinocytes; /, Ikka/ keratino-
cytes. Ras-GTP, active form of Ras; AG1478, EGFR inhibitor;
N17, dominant-negative Ras mutant; V61, active Ras mutant.
(B) Effects on filaggrin expression in Ikka/ keratinocytes by
the indicated proteins, as detected by western blotting.
b-actin was used as a loading control.
(C) Effects on colony formation of Ikka/ keratinocytes by the
indicated proteins. Colonies were stained with 0.5% crystal
violet.
(D) Effects on filaggrin expression in Ikka+/+ keratinocytes
by the indicated proteins, as detected by western blotting.
b-actin was used as a loading control.
(E) A working hypothesis of IKKa function in keratinocytes for
maintaining skin homeostasis and preventing skin cancer.
Arrows indicate promotion; blunted line indicates inhibition.222 Cancer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc.
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uncontrolled proliferation is able to block terminal differentiation
at different stages, allowing a single cell to grow into a mass.
Additional alterations cause the mass to irreversibly invade and
become malignant. Hair follicular keratinocytes targeted by
Ras efficiently develop into malignant tumors because skin
stem cells located there are thought to be targeted by the tumor
initiator (Brown et al., 1998; Kangsamaksin et al., 2007).
Here we showed that IKKa deletion in keratinocytes results in
skin carcinomas that resemble DMBA/TPA-induced tumors (Fig-
ures 7D and 7F). In IKKa-deficient keratinocytes, elevated Ras
activity, which is incorporated into the EGFR-driven loop, and
elevated expression of multiple growth factors, integrins, cyto-
kines, and MMPs provide the molecular bases for promotion of
keratinocyte proliferation and transformation in vivo (Figure 3E;
Figures 8A–8D). Inactivation of EGFRor reintroduction of IKKa in-
duces terminal differentiation, inhibits hyperproliferation in IKKa-
deficient keratinocytes (as described above), andprevents tumor
development. These results underscore the importance of IKKa-
mediated terminal differentiation as an innate, primary mecha-
nism for preventing skin carcinogenesis. In addition to the effect
of EGFR on keratinocyte differentiation, Sibilia et al. (2000) re-
ported that inactivation of EGFR prevents overexpressed SOS-
F-induced skin tumors through a survival pathway but does not
affect ERK activity, which suggests that overexpressed SOS-F
and IKKa loss may affect different internal cellular pathways.
Treatment with TPA or EGF was found to attenuate binding of
IKKa to the promoters of growth factors, which was accompa-
nied by the elevated expression of their corresponding genes
(Figures 5A–5I). Previously, TPA, ultraviolet radiation, and/or
ETS-1, a proto-oncogenic protein, were found to upregulate
IKKa expression (Gu et al., 2004; Li and Karin, 1998; Park
et al., 2007). Elevated expression of IKKa may suppress the ac-
tivities of its targets to ensure that excessive numbers of kerati-
nocytes undergo terminal differentiation, thereby preventing cell
proliferation and tumor formation. Moreover, p63 regulates IKKa
expression, and impaired Ikka may affect p63-related tumor
development (Koster et al., 2007). DNA methylation has been
shown to downregulate IKKa expression in human oral SCCs
(Maeda et al., 2007). IKKa prevents DNA methylation of the
14-3-3s gene (Zhu et al., 2007). It will be interesting to see
whether IKKa can be self-regulated in an epigeneticmanner. Col-
lectively, these results indicate that IKKa executes its role as
a surveillant in preventing skin cancer through multiple avenues.
We observed that IkkaF/F/MMTV.Cre mice developed carcino-
masonly on their faces, andmost of the tumors in IkkaF/F/K15.Cre
mice were close to the neck and face. It is possible that microen-
vironmental conditions, such as the presence of more blood
microvessels in the face than in dorsal skin,mayhave contributed
to these phenotypes. Finally, we would like to emphasize that
western blotting using commercial antibodies against IKKa
detects a strong, nonspecific band closely underneath the IKKa
protein in tissue lysates, but not in culturedcell lysates. Therefore,
proper techniques can avoid misleading findings and help us to
understand the physiological functions of IKKa.
Perspectives
Here we have identified the pathway that IKKa utilizes in its role
as a keratinocyte proliferation and differentiation switch, whichCais required for maintaining skin homeostasis and preventing
skin cancer. Although many deregulated genes were identified
in IKKa-deficient keratinocytes, it remains to be elucidated
how IKKa crosstalks with other pathways. It will also be impor-
tant to develop new tools to identify the target cells of IKKa-
deletion-induced skin tumors, which will facilitate the design
of efficient therapeutic drugs to battle cancer. Stem cells are
thought to be targets for most skin tumors (Kangsamaksin
et al., 2007). It remains to be determined whether suprabasal
keratinocytes are resistant to dedifferentiation and whether
hair follicle keratinocytes or daughters of stem cells are resistant
to differentiation when IKKa is absent during carcinogenesis.
Also, how microenvironmental inflammation interacts with can-
cer-initiating cells remains to be defined. In addition, it will be
important to determine whether IKKa plays a role in stem cell
maintenance, renewal, and division. Overall, these animal
models provide good opportunities for understanding many fun-
damental biological questions and identifying new therapeutic
targets for preventing cancer.
EXPERIMENTAL PROCEDURES
Mice
Tnfr1/ mice (stock number 002818) on a C57BL/6 background and
Egfrwa2/wa2 mice (stock number 000317) on a C57BL/6 background were pur-
chased from The Jackson Laboratory. Egfr+/ mice on a CD-1 background
(stock number 002857) were purchased from The Jackson Laboratory 3.5
years ago. These mice were backcrossed with our Ikka+/ mice on a 129/
C57BL/6 background for over six generations. The Egfr+/ mice were then
crossed with IkkaF/F mice on a 129/C57BL/6 background. MMTV.Cre mice
(stock number 003553) were purchased from The Jackson Laboratory. These
mice were on a B6/129 background, but the strain originated on an FVB back-
ground. GW2974 (GlaxoSmithKline), an inhibitor of EGFR and ErbB2, was used
in the diet at 200 ppm as described previously (Kiguchi et al., 2005). Pregnant
mothers of IkkaF/F/K5.Cre embryos (Brakebusch et al., 2000; Lopez-Rovira
et al., 2005) received the diet containing GW2974 at 13 days postcoitum.
IkkaF/F/K15.Cre mice (stock number 005249; strain name B6;SJL-Tg(Krt1-
15-cre/PGR)22Cot/J) at 4 to 6 weeks of age (Morris et al., 2004) received the
diet containing GW2974 and were treated 1 week later with RU486 (M8046,
Sigma-Aldrich). RU486 (40 mg) in 200 ml of acetone was applied topically to
the dorsal mouse skin every day for 10 days. Tamoxifen-inducible K5.Cre
mice were obtained from P. Chambon (Indra et al., 1999). The dorsal skin of
IkkaF/F/K5.Cre mice at age 6–8 weeks was shaved and treated topically with
tamoxifen (1 mg per mouse in 200 ml ethanol; catalog no. T5648, Sigma) every
day for 14 days.
IkkaF/F Mice
To create the mouse lines used in this study, an 8.86 kb genomic DNA frag-
ment containing exons 3–9 of the Ikka gene was isolated from R1 ES cells
on a 129 background, cloned into the pBluescript II SK+ vector, and
sequenced. A neomycin cassette fragment with loxP sites at both ends was
inserted into intron 6 (Cao et al., 2001). One loxP site was created in intron
9. The construct plasmid DNA was linearized with ClaI and electroporated to
R1 ES cells, and the ES cells were selected using G418 in the Genetically
Engineered Mouse Facility at the M.D. Anderson Cancer Center. Using South-
ern blotting, 166 clones were screened, 11 of which were found to be positive
for homologous recombination. The neomycin cassette was deleted by intro-
ducing aCre vector (Cao et al., 2001). Cre recombination can thus induce a de-
letion from exon 6 to 8, resulting in a frameshift for IKKa. Three ES cell clones
with the floxed Ikka allele were identified by Southern blot analysis and used to
generate chimeras. The chimeras were backcrossedwithWTC57BL/6mice to
generate IkkaF/+ mice. The IkkaF/+ mice obtained from the three ES cell colo-
nies were identical. The IkkaF/+ mice were intercrossed to generate IkkaF/F
mice on a 129/C57BL/6 background, which were normal.ncer Cell 14, 212–225, September 9, 2008 ª2008 Elsevier Inc. 223
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All mice used in this study were cared for in accordance with the guidelines of
the Institutional Animal Care and Use Committee of The University of Texas
M.D. Anderson Cancer Center (animal protocol 04-01-05732).
Keratinocyte Culture
Mouse primary keratinocytes were isolated and cultured as described previ-
ously (Hu et al., 2001). Briefly, skin specimens isolated from newborn mice
or E19 embryos were treated with 0.25% trypsin (15050-065; Invitrogen) for
8 to 10 hr at 4C, and the epidermis was separated from the dermis. The iso-
lated keratinocytes were plated on 60 cm cell dishes containing keratinocyte
serum-free medium (10785; GIBCO). To determine cell growth curves, equal
numbers of different types of cells were plated and then counted on the
days indicated in the figures. The cells were treated with 0.02 mM AG1478
(658552; Calbiochem), 20 mM GM6001 (364205; Calbiochem), 5 mM
GW2974, and/or 30 mM PD98059 (B59034; Calbiochem). Reintroduction of
different IKKa forms in cultured keratinocytes was performed as described
previously (Hu et al., 2001). To analyze cell proliferation, 2 3 105 cells were
plated on each dish. Cell colonies were then fixed in 100% ethanol for 20 min
at 20C, stained with 0.5% crystal violet solution (HT901-8F0Z; Sigma) for
15 min, and washed with H2O.
ACCESSION NUMBERS
Original microarray data have been deposited at the NCBI Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with the accession number
GSE12111.
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The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, eighteen figures, and one table and can be found
with this article online at http://www.cancercell.org/cgi/content/full/14/3/
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